Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL271526 | 0.99 | CYP3A4 (0.52) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL12249474 | 0.85 | RAB9A (0.58) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL10202835 | 0.80 | LMNA (0.58) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2736250 | 0.80 | TDP1 (0.57) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2736245 | 0.78 | RAB9A (0.53) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2984056 | 0.78 | CYP3A4 (0.80) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2984777 | 0.78 | CYP3A4 (0.80) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL2974013 | 0.78 | CYP3A4 (0.80) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4961426 | 0.77 | TDP1 (0.58) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL272743 | 0.77 | CYP3A4 (0.79) | CYP3A4NPC1RAB9ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | claimed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CYP3A4 18/4885NPC1 294/4885RAB9A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.